ÂÜÀòÂÒÂ×

Owen is an Investment Director at 4BIO Capital with significant experience working with early-stage biotechnology companies.

Owen is currently a Director at Locki Therapeutics, and while at Arix Bioscience, previously acted as an Observer on the boards of LogicBio and Depixus.

Owen holds a Masters of Science in Experimental and Translational Therapeutics from the University of Oxford in and is also qualified as an accountant, having spent several years working in assurance and advisory roles at Grant Thornton with public and private clients.